戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sion or of cognitive therapy compared with a monoamine oxidase inhibitor.
2 es and aromatic amino acid decarboxylase and monoamine oxidase inhibitors.
3 at such patients responded preferentially to monoamine oxidase inhibitors.
4 st and present clinical trials of tricyclic, monoamine oxidase inhibitor, and selective serotonin reu
5  side effects commonly seen with traditional monoamine oxidase inhibitor antidepressants were not obs
6  dose response experiments with tricyclic or monoamine oxidase inhibitor antidepressants.
7                                     Although monoamine oxidase inhibitors are effective in treating a
8         In this study, administration of the monoamine oxidase inhibitors clorgyline and deprenyl res
9  selective serotonin reuptake inhibitors and monoamine oxidase inhibitors did not show significant pr
10 ive to standard acute-phase treatment with a monoamine oxidase inhibitor for outpatients with major d
11 re potentiated by addition of the vertebrate monoamine oxidase-inhibitor hydrazaline.
12 f smoking behavior in humans and presence of monoamine oxidase inhibitors in tobacco smoke, we hypoth
13 reated with beta-blockers, ACE inhibitors or monoamine oxidase inhibitors, in children under 5 years
14 covery of a new class of compounds acting as monoamine oxidase inhibitors (MAO-Is) and bearing a 6'-s
15 ibitor (SSRI) fluoxetine (10 mg/kg), and the monoamine oxidase inhibitor (MAOI) phenelzine (10 mg/kg)
16   Hamsters were treated chronically with the monoamine oxidase inhibitor (MAOI), clorgyline, and then
17                                      Because monoamine oxidase inhibitors (MAOI) are often more effec
18                       We previously assessed monoamine oxidase inhibitors (MAOIs) for their ability t
19 n of LSD1 or inhibition of its activity with monoamine oxidase inhibitors (MAOIs) results in the accu
20 been treated with tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), fluoxetine, or pla
21  is a small body of evidence indicating that monoamine oxidase inhibitors may be effective in at leas
22                          While tricyclic and monoamine oxidase inhibitor medications were associated
23       However, neither pargyline, a specific monoamine oxidase inhibitor, nor semicarbazide, a specif
24                   Earlier research has shown monoamine oxidase inhibitors or benzodiazepines to be ef
25 e inhibitors desipramine and reboxetine, the monoamine oxidase inhibitor pargyline, and the atypical
26    Our lab has found opposing effects of the monoamine oxidase inhibitor phenelzine and the tricyclic
27  group therapy (CBGT) and treatment with the monoamine oxidase inhibitor phenelzine sulfate for socia
28 reuptake inhibitor desipramine (DMI), or the monoamine oxidase inhibitor phenelzine.
29 n has also been introduced in a study of the monoamine oxidase inhibitor rasagiline, demonstrating a
30  selective serotonin reuptake inhibitor or a monoamine oxidase inhibitor rather than a tricyclic anti
31                   Combined with pargyline, a monoamine oxidase inhibitor, reserpine increased catecho
32 total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), al
33 clusively among PD patients treated with the monoamine oxidase inhibitor selegiline (L-deprenyl).
34        As part of the clinical trials of the monoamine oxidase inhibitor selegiline for treating coca
35 ects on outcomes compared with waitlist were monoamine oxidase inhibitors (SMD -1.01, 95% credible in
36 cal depression are more likely to respond to monoamine oxidase inhibitors than to tricyclic antidepre
37 n by RNAi in human erythroid cells or by the monoamine oxidase inhibitor tranylcypromine in human ery
38 uoxetine) or norepinephrine (desipramine), a monoamine oxidase inhibitor (tranylcypromine), and elect
39 ective reuptake inhibitor (fluoxetine), or a monoamine oxidase inhibitor (tranylcypromine).
40 studies of the neuroprotective properties of monoamine oxidase inhibitors, we found that phenelzine p
41 idepressants (eg, tricyclic antidepressants, monoamine oxidase inhibitors) were excluded.
42 ibitor) and tranylcypromine (10 mg/kg, i.p., monoamine oxidase inhibitor) with each drug being inject

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。